Featured in Newsweek
Read about us in the August 2017 issue
About Us

NanoCliq is is an exciting new life sciences company based in the Advanced Technology Development Center in Atlanta, Georgia. Formed in 2016 by founders from Georgia Tech, our company is developing a new class of vaccine by leveraging protein nanoparticle technology to stimulate and train the immune system to fight parasitic diseases. NanoCliq’s vaccine for Leishmaniasis is built on the novel nQ nanoplatform conjugated with a specialized carbohydrate signature specific for the parasite. Studies conducted with our collaborating lab in Brazil, a region where Leishmania is endemic, have demonstrated complete protection from the disease in challenged laboratory animals.

Our Mission

NanoCliq’s mission is the development of innovative vaccines and immunotherapies to address emerging disease on a global scale.
Core Team
Indra Datta

Indra Datta

CEO

Indra has over 12 years of experience working in management and startups.

He is a former tech executive, CTO at Ultramarine Inc., founder of MDVault medical software, technical specialist for ExxonMobil and consultant at Cox.

He holds Masters degrees in engineering and business from Rice University and Georgia Tech.

Robert Demont

Robert Demont

CSO

10+ years laboratory research experience with 6 years focused on new vaccine development, 3+ years technology commercialization experience

Lowell Pratt

Lowell Pratt

COO

9+ years program management experience at an economic development entity in a healthcare-based community as well as at the largest technology council in the country. Managed an angel network and worked for a private equity firm.

Recent Posts